Article & News

NEW DELHI: A citizen-funded quality study of commonly prescribed medicines has found no difference in quality between expensive branded drugs and the far cheaper generics,

Mumbai, 27 January 2026 — India’s healthcare landscape is undergoing a -structural shift as consumers increasingly take charge of everyday health decisions, as per a

Mainland China could become one of the first markets in the world to approve a drug fully designed by artificial intelligence, as advances in AI

India’s first wave of generic semaglutide approvals is underway, as multiple domestic drugmakers secure clearances for obesity and metabolic treatments, setting the stage for lower-cost

Japan Drug Based on Gene Therapy Market Size, Strategic Outlook & Forecast 2026-2033Market size (2024): $5.2 billionForecast (2033):CAGR 2026-2033: 16.5%1.0 Strategic Assessment of Japan Drug

The pharmaceutical industry in the country has flagged the recent CDSCO’s norm mandating a minimum 60% shelf life for exported drugs as a significant hurdle,

Metabolic medicine dominated the health headlines in 2025 — and looks set to do so again in 2026.In 2025, GLP-1 weight-loss drugs, a new class

NEW DELHI: A citizen-funded quality study of commonly prescribed medicines has found no difference in quality between expensive branded drugs and the far cheaper generics,

The decision follows a proposal by the CDSCO, top internal advisory body-the Drugs Consultative Committee (DCC), which at its 67th meeting last month had also

Facing mount­ing scru­tiny over drug safety lapses, India is work­ing to over­haul its phar­ma­ceut­ical licens­ing frame­work by intro­du­cing a sep­ar­ate whole­sale licens­ing regime for bulk